in vivo reprogramming for next-generation CAR-T therapy
Alaya.bio is a preclinical-stage biotech company developing in vivo CAR-T cell therapies. Our proprietary targeting polymeric nanoparticle platform combines the biological efficiency of lentiviral gene delivery with the precision of synthetic polymer chemistry to reprogram immune cells directly inside the patient's body.
The problem with existing CAR-T cell therapies
The CAR-T Cell Therapy Bottleneck
Patient’s access to current CAR-T cell therapies is limited because it requires highly specialized care centers, long and complex vein-to-vein time and the cost for community and the patient is high.
Each treatment begins with apheresis, where a patient’s T cells are extracted and shipped to a specialized facility. There, cells are genetically engineered, expanded for weeks, quality controlled and, shipped back for infusion to the patient.
Each step creates unavoidable delays:
Patients wait several weeks while their disease progresses.
For patients outside major medical centers, access is very complicated.
The result is that, depending on location, only around 10-30% of eligible patients ever receive CAR-T therapy
Our solution
in vivo CAR-T cell therapy delivery
Using our targeting polymeric nanoparticle platform technology
Our platform delivers genetic instructions directly to circulating T cells, reprogramming them inside the body to target and eliminate cancer cells and autoreactive immune cells.
Our approach addresses fundamental limitations of ex vivo cell therapy, dramatically reduces cost and complexity while expanding access to patients who cannot reach or wait for ex vivo therapy.
Our technology
in vivo CAR-T Cell Engineering
Alaya.bio’s targeting polymeric nanoparticle platform delivers genetic instructions directly to circulating T cells. Our nanoparticles encapsulate lentiviral vectors carrying CAR transgenes, target T cell populations in the bloodstream, and enable in vivo transduction and reprogramming.
This eliminates the extract-manipulate-reinfuse cycle of traditional CAR-T therapy. No apheresis. No specialized manufacturing facilities. No weeks of production time.
The result: therapy delivered where and when patients need it, with the potential for repeat dosing and broader population access.
Competitive advantages
Targeted Biodistribution
Engineered delivery designed to support selective immune cell targeting while limiting off-target exposure
Redosing Potential
Reduced immunogenicity enables iterative administration strategies and repeat dosing
Defensible IP Position
Broad patent coverage across polymers, targeting agents, cargo, and platform architecture
Modular Platform Architecture
Plug-and-play design adaptable to multiple targets, payloads, and future indications
About Us
Alaya.bio is a preclinical-stage biotechnology company developing in vivo CAR-T cell therapies using a proprietary targeting polymeric nanoparticle platform.
Our team brings expertise in gene and cell therapy, with experience spanning platform development and translational research.
Partnering for Targeted Delivery
Beyond Alaya.bio’s internal programs, our targeting polymeric nanoparticle platform can enable targeted delivery across multiple therapeutic areas. We see clear opportunities for collaborative programs with partners who bring deep expertise in target biology and drug development.
Alaya.bio welcomes the opportunity to work with biotech and pharma partners to deliver their payloads to the right cells, in the right tissues, at the right time.
Contact us
We welcome enquiries from partners interested in exploring how Alaya.bio's platform could support your programs.
Please share a brief overview of your organization, your area of therapeutic interest, and the type of collaboration you have in mind. Our team will review your submission and aim to respond within two business days.
USA (Headquarters)
167 Madison Avenue, Ste 205 #4748,
New York City, NY 10016, USA
France (R&D)
1 mail du Professeur Georges Mathé
94800 Villejuif, FRANCE